文献速递传染病防控与疫情报告免疫规划

TiterMax Gold®佐剂中重组MRLC(肌球蛋白调节轻链)抗原对实验性大鼠片形吸虫病的免疫保护作用

Immune protection conferred by recombinant MRLC (myosin regulatory light chain) antigen in TiterMax Gold® adjuvant against experimental fasciolosis in rats.
PubMed 文献 · Vaccine · 2016-12-23

研究将重组肌球蛋白调节轻链(MRLC)抗原配以TiterMax Gold®佐剂免疫大鼠,评估其对实验性片形吸虫病的保护效果。四组每组15只动物中,免疫感染组较佐剂对照组虫负荷降低51.0%(p<0.001),较未免疫感染组降低61.5%(p<0.001),粪卵排出量分别降低44.8%和37.3%但无统计学显著差异。免疫组在慢性感染期TNF-alpha和IL-2升高、IL-4降低(p<0.05),早期IFN-gamma升高(p<0.05),提示混合Th1/Th2应答但以Th1为主。

要点

  • MRLC+TiterMax Gold®免疫组较佐剂对照组虫负荷降低51.0%(p<0.001),较未免疫感染组降低61.5%(p<0.001)。
  • 粪卵排出量较未免疫感染组和佐剂对照组分别降低44.8%和37.3%,差异无统计学显著。
  • 慢性期TNF-alpha和IL-2升高、IL-4降低,早期IFN-gamma升高(p<0.05),以Th1为主。

核心结论

  • 重组MRLC抗原免疫可显著降低大鼠片形吸虫虫负荷并增强Th1免疫应答,作者认为需进一步研究以提高疫苗效力。

研究设计与样本

  • 实验性试验设四组,每组15只大鼠:组1未免疫感染、组2 MRLC加佐剂免疫后感染、组3仅佐剂免疫后感染、组4未免疫未感染。

主要发现

  • 组2较组3虫负荷降低51.0%(p<0.001),较组1降低61.5%(p<0.001)。
  • 组2粪卵排出量较组1降低44.8%、较组3降低37.3%,差异无统计学显著。
  • 慢性感染期组2 TNF-alpha和IL-2水平较高、IL-4较低(p<0.05),感染早期IFN-gamma较高(p<0.05)。
  • 组2安乐死时抗MRLC血清IgG水平显著高于对照组(p<0.05)。

关键数值与推荐

  • 虫负荷降低:组2 vs 组3为51.0%(p<0.001),组2 vs 组1为61.5%(p<0.001)。
  • 粪卵排出降低:组2 vs 组1为44.8%,组2 vs 组3为37.3%,均无统计学显著差异。
  • 细胞因子:慢性期组2 TNF-alpha和IL-2较高、IL-4较低(p<0.05),早期IFN-gamma较高(p<0.05)。
  • 抗MRLC血清IgG:组2在安乐死时显著高于对照组(p<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者在结论中提出需进一步研究以提高疫苗效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Protection against experimental fasciolosis in rats immunized with recombinant myosin regulatory light chain (MRLC) in TiterMax Gold® adjuvant was assessed. The experimental trial consisted of four groups of 15 animals; group 1 was unimmunized and infected, group 2 was immunized with MRLC in adjuvant and infected, group 3 was infected and immunized with adjuvant only and group 4 was unimmunized and uninfected. Immunization with MRLC in TiterMax Gold® adjuvant (group 2) induced a reduction in fluke burdens of 51.0% (p<0.001) when compared with the adjuvant control group, and 61.5% (p<0.001) when compared with the unimmunized infected controls. There was a reduction in fecal egg output in group 2 of 44.8% and 37.3% compared with group 1 and group 3, respectively; although this difference was not statistically significant. Measurement of cytokine levels revealed higher levels of TNF-alpha and IL-2 as well as lower levels of IL-4 in group 2 during the chronic stage of infection (p<0.05), along with higher levels of IFN-gamma during early stages of infection (p<0.05). These results suggest a mixed Th1/Th2 phenotype immune response; however predominance of Th1 cytokines was observed. Levels of anti-MRLC serum IgG in group 2 were significantly higher than controls at the time of euthanasia (p<0.05). This is the first report of immunization with recombinant MRLC in rats, demonstrating that this antigen significantly reduces fluke burdens, increases the Th1 immune response and encourages further studies to improve the vaccine's efficacy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Henker LC, Schwertz CI, Lucca NJ, et al. Immune protection conferred by recombinant MRLC (myosin regulatory light chain) antigen in TiterMax Gold® adjuvant against experimental fasciolosis in rats. Vaccine. 2016. PMID: 28024953. doi:10.1016/j.vaccine.2016.11.092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。